Aug 19, 2026, 11:00 UTC
Mochida Pharmaceutical succeeded the manufacturing and marketing approval for the gout and hyperuricemia treatment 'Topirolic' from Fuji Pharmaceutical and acquired related assets including intellectual property rights.
Source: